ImmuCell Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	30.68	27.64	26.49	17.47	18.57	19.24
Revenue Growth	8.49%	4.35%	51.63%	-5.90%	-3.51%	25.42%
Cost of Revenue	18.31	16.2	18.55	13.6	10.92	10.59
Gross Profit	12.37	11.45	7.94	3.87	7.65	8.66
Selling, General & Admin	8.61	6.75	5.68	5.22	5.45	4.23
Research & Development	1.89	3.04	3.9	4.39	4.49	4.17
Other Operating Expenses	2	-	-	-	-	-
Total Operating Expenses	12.5	9.8	9.58	9.62	9.95	8.4
Operating Income	3.87	1.65	-1.64	-5.75	-2.3	0.26
Total Non-Operating Income (Expense)	-3.01	-2.68	-0.51	-0.02	-0.19	-0.33
Pretax Income	0.85	-1.03	-2.15	-5.77	-2.49	-0.07
Provision for Income Taxes	0.07	0.01	0.01	0	0.01	0.01
Net Income	0.79	-1.04	-2.16	-5.77	-2.49	-0.08
Net Income to Common	0.79	-1.04	-2.16	-5.77	-2.49	-0.08
Net Income Growth	-55.31%	-	-	-	-	-
Shares Outstanding (Basic)	9	9	8	8	8	8
Shares Outstanding (Diluted)	9	9	8	8	8	8
Shares Change	3.46%	10.52%	5.42%	0.03%	2.01%	5.25%
EPS (Basic)	0.07	-0.12	-0.26	-0.75	-0.32	-0.01
EPS (Diluted)	0.07	-0.12	-0.26	-0.75	-0.32	-0.01
EPS Growth	-63.16%	-	-	-	-	-
Free Cash Flow	4.21	1.22	-0.11	-6.57	-5.52	-1.65
Free Cash Flow Growth	138.91%	-	-	-	-	-
Free Cash Flow Per Share	0.46	0.14	-0.01	-0.85	-0.71	-0.22
Gross Margin	40.32%	41.40%	29.97%	22.15%	41.19%	44.98%
Operating Margin	12.60%	5.97%	-6.19%	-32.90%	-12.38%	1.34%
Profit Margin	2.57%	-3.76%	-8.14%	-33.05%	-13.43%	-0.41%
FCF Margin	13.74%	4.43%	-0.41%	-37.59%	-29.72%	-8.60%
EBITDA	6.25	4.38	1.05	-3.03	0.19	2.72
EBITDA Margin	20.38%	15.84%	3.95%	-17.35%	1.02%	14.13%
EBIT	3.87	1.65	-1.64	-5.75	-2.3	0.26
EBIT Margin	12.60%	5.97%	-6.19%	-32.90%	-12.38%	1.34%
Effective Tax Rate	7.76%	-1.12%	-0.47%	-0.08%	-0.31%	-13.26%

SEC Filings: 10-K · 10-Q